Annual report pursuant to Section 13 and 15(d)

SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)

v3.22.0.1
SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2022
Feb. 28, 2021
Jan. 31, 2021
Oct. 31, 2020
Feb. 29, 2020
Dec. 31, 2019
Oct. 31, 2019
Jan. 31, 2019
Oct. 31, 2018
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Collaborations                          
Upfront payment received                     $ 125,000    
Accretion expense                     2,800    
Accounts receivable                     15,472 $ 15,973  
Collaborative Arrangement [Member]                          
Collaborations                          
Contingent payments                     1,300,000    
License agreement with unrelated third party                          
Collaborations                          
Revenue recognized                     4,000    
Proceeds from License Fees Received   $ 4,000                      
One-time fee received from license rights granted   $ 4,000                      
Specified Development Events [Member] | Collaborative Arrangement [Member]                          
Collaborations                          
Contingent payments                     279,500    
Specified Regulatory Events [Member] | Collaborative Arrangement [Member]                          
Collaborations                          
Contingent payments                     285,600    
Specified Product Launch Events [Member] | Collaborative Arrangement [Member]                          
Collaborations                          
Contingent payments                     778,500    
Development and regulatory milestones by non-CNS disease products                          
Collaborations                          
Contingent payments                     330,000    
Development and regulatory milestones by non-CNS disease products | Milestone payments on a product-by-product basis                          
Collaborations                          
Contingent payments                     100,000    
Development and regulatory milestones by CNS disease products                          
Collaborations                          
Contingent payments                     255,000    
Development and regulatory milestones by CNS disease products | Milestone payments on a product-by-product basis                          
Collaborations                          
Contingent payments                     150,000    
Grifols                          
Collaborations                          
Contingent payments                     277,500    
Upfront payment received       $ 30,000       $ 30,000          
Revenue recognized                   $ 20,000      
Deferred revenue                     700 1,600  
Nonrefundable upfront payment       $ 5,000                  
Revenue, cumulative catch-up                   $ 25,000      
Grifols | Licensed Rights                          
Collaborations                          
Revenue recognized                       39,900  
Grifols | Research Services                          
Collaborations                          
Revenue recognized                       3,800  
Grifols | Delivery of drug supply for commercialization                          
Collaborations                          
Revenue recognized                       700  
Grifols | Exercise of option to include additional territories                          
Collaborations                          
Revenue recognized                       500  
Grifols | Research and Regulatory Services Performed and License Right                          
Collaborations                          
Revenue recognized                         $ 4,700
Grifols | Commercial Milestones                          
Collaborations                          
Contingent payments               $ 297,500          
Revenue recognized                     2,000    
Kissei                          
Collaborations                          
Contingent payments                 $ 147,000        
Upfront payment received                 $ 33,000        
Revenue, remaining performance obligation                     33,000    
Deferred revenue                     1,400 1,400  
Lilly                          
Collaborations                          
Deferred revenue                     500    
Daiichi Sankyo [Member] | Collaborative Arrangement [Member]                          
Collaborations                          
Revenue recognized                     1,800 2,100  
fostamatinib                          
Collaborations                          
Revenue recognized                     10,500    
Government contract     $ 16,500                    
Remaining amount of government award expected to be received in succeeding periods                     6,000    
fostamatinib | Maximum                          
Collaborations                          
Government contract     $ 16,500                    
fostamatinib | Grifols                          
Collaborations                          
Collaborative payment received         $ 20,000                
Markup percentage           30.00%              
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                          
Collaborations                          
Collaborative payment received         17,500                
fostamatinib | Grifols | Creditable advance royalty payment                          
Collaborations                          
Collaborative payment received         $ 2,500                
fostamatinib | Kissei                          
Collaborations                          
Revenue recognized                       300 1,600
fostamatinib | Medison Pharma | Financing arrangement                          
Collaborations                          
Upfront payment received             $ 5,000            
Financing liability with accreted interest expense                     5,600 5,000  
Deferred revenue                     200    
Accrued interest                     400 $ 0 $ 0
fostamatinib | Medison Pharma | Commercial and license agreements                          
Collaborations                          
Revenue recognized                     $ 100    
R552                          
Collaborations                          
Company's percentage of development costs                     20.00%    
Financing component liability                     $ 57,900    
Financing liability interest accretion discount rate                     6.40%    
Financing liability with accreted interest expense                     $ 60,700    
Revenue, remaining performance obligation                     67,100    
R552 | Maximum                          
Collaborations                          
Funding commitment                     65,000    
Non-CNS penetrant IP                          
Collaborations                          
Revenue recognized                     60,400    
Non-CNS penetrant IP | Licensed Rights                          
Collaborations                          
Revenue, remaining performance obligation                     6,700    
CNS penetrant IP                          
Collaborations                          
Revenue recognized                     6,200    
Research and development services | Grifols                          
Collaborations                          
Revenue recognized                     $ 900    
Subsequent event | R552                          
Collaborations                          
Payment of cost share to collaboration partner $ 2,100